Metrics to compare | XBRANE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXBRANEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −0.5x | −0.2x | |
PEG Ratio | 0.00 | 0.40 | 0.00 | |
Price/Book | 0.4x | 2.9x | 2.6x | |
Price / LTM Sales | 1.8x | 5.7x | 2.7x | |
Upside (Analyst Target) | 47.8% | 355.9% | 66.0% | |
Fair Value Upside | Unlock | 27.4% | 10.8% | Unlock |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.